# Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment

> **NCT04981379** · PHASE3 · COMPLETED · sponsor: **Health Institutes of Turkey** · enrollment: 1120 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Favipiravir
- **DRUG:** Favipiravir + Hydroxychloroquine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04981379
- **Lead sponsor:** Health Institutes of Turkey
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-16
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-02-16
- **Target enrollment:** 1120 (ACTUAL)
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04981379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04981379, "Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04981379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*